Barbara G. Duncan's most recent trade in Atea Pharmaceuticals Inc was a trade of 41,200 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 29,600 | 0 | - | - | Restricted Stock Units | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 29,600 | 62,750 | - | 0 | Common Stock | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,750 | 5,750 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,165 | 19,919 (0%) | 0% | 0 | Common Stock | |
| Ovid Therapeutics Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Ovid Therapeutics Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 0 | - | - | Restricted Stock Units | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 33,150 | - | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 8,804 | 8,804 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 6,501 | 15,754 (0%) | 0% | 0 | Common Stock | |
| Ovid Therapeutics Inc | Barbara Duncan G. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 46,750 | 46,750 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 33,150 | 33,150 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 11,371 | 11,371 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 8,065 | 9,253 (0%) | 0% | 0 | Common Stock | |
| Ovid Therapeutics Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Halozyme Therapeutics Inc. | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 1,188 | 1,188 (0%) | 0% | 0 | Common Stock | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 61,264 | 61,264 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 17,000 | 17,000 | - | - | Stock Opion (Right to Buy) | |
| Ovid Therapeutics Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2022 | 21,347 | 21,347 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 17,000 | 17,000 | - | - | Stock Opion (Right to Buy) | |
| Ovid Therapeutics Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 1,750 | 1,750 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Barbara G. Duncan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) |